Has Muhammad Khawaja, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,554 in general payments to Muhammad Khawaja, MD across 8 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Muhammad Khawaja, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Muhammad Khawaja, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Muhammad Khawaja, MD

Hematology & Oncology · Bel Air, MDNPI 1871724153

Payments from drug & device makers

What this record shows

This record is dominated by education: $2,139 of the $2,554 with a category attached, or 83.8%. Eli Lilly accounts for 87.4% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $2,305, more than ten times the $13 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in MD, where the typical reported total is $2,111.

$2,554in general payments, 2019–2025

Across 8 payments — averaging $319.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Eli Lilly$2K
E.r. Squibb & Sons, L.L.C.$165
Beigene USA, Inc.$70
Caris MPI, Inc.$59
Stryker$15
Amgen$13

$1,015,766in research payments, 2019–2025

Across 128 payments — averaging $7935.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Genentech, Inc.$460K
Eli Lilly$334K
Springworks Therapeutics, Inc.$148K
Y-mabs Therapeutics, Inc.$39K
Beigene USA, Inc.$24K
Beone Medicines USA, Inc.$12K

What the payments were for

Food & beverage$41516%
Education$2,13984%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Eli Lilly	2	$2,232
E.r. Squibb & Sons, L.L.C.	2	$165
Beigene USA, Inc.	1	$70
Caris MPI, Inc.	1	$59
Stryker	1	$15
Amgen	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Reblozyl$146

How this compares

$2,554 in reported general payments places this provider in the 50th percentile of 242 hematology & oncology providers in Maryland.

See all hematology & oncology providers in Maryland →

Medicare billing

Part B allowed, 2024

$27,898

Medicare patients

Services billed

342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
CreonLipase/Protease/Amylase	16	$36,843
Olanzapine	24	$503
Potassium Chloride	13	$391
Ondansetron OdtOndansetron	16	$386
Dexamethasone	11	$317
Prochlorperazine Maleate	13	$215

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Bel Air

Ralph BocciaBethesda$3.1M
Sandra SwainBethesda$1M
Kashif AliSilver Spring$987K
Ani BalmanoukianBaltimore$842K
Benjamin LevyBaltimore$578K
Patrick FordeBaltimore$269K
Noah HahnBaltimore$133K
Walid El AyassSalisbury$111K
Arun BhandariAnnapolis$103K
Huzefa BahrainBaltimore$102K

See the full list for Maryland →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →